Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Generic Name
- Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于：1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染；
2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥；
3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员；
4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少；
5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。
- Associated Conditions
- -
- Associated Therapies
- -
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Interventions
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 22
- Registration Number
- NCT01266083
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant
- Conditions
- Interventions
- First Posted Date
- 2010-08-03
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT01174082
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Novel Interventions in HIV-1 Infection
- Conditions
- Interventions
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2013-09-04
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 12
- Registration Number
- NCT01130376
- Locations
- 🇬🇧
St. Stephen's AIDS Trust, London, United Kingdom
Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
- Conditions
- Interventions
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 13
- Registration Number
- NCT00952237
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells
- Conditions
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2016-07-15
- Lead Sponsor
- Hoag Memorial Hospital Presbyterian
- Target Recruit Count
- 56
- Registration Number
- NCT00948480
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2009-04-13
- Lead Sponsor
- Acute Leukemia French Association
- Target Recruit Count
- 473
- Registration Number
- NCT00880243
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod
- Conditions
- Interventions
- First Posted Date
- 2008-11-27
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT00799110
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham & Women's Hospital, Boston, Massachusetts, United States
Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2017-08-23
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 30
- Registration Number
- NCT00678054
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
- Conditions
- Interventions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2016-11-29
- Target Recruit Count
- 53
- Registration Number
- NCT00661622
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT00631072
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.